Latest / Flash Stock Reports (Video)
ACXP Trades Below Cash with a 0% Recurrence Drug
ACXP achieves 0% recurrence in clinical trials — biotech stock analysis and valuation 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends In this deep dive, we break down Acurx Pharmaceuticals, Inc. (ACXP) and its lead clinical-stage pipeline candidate ibezapolstat targeting Clostridioides difficile infection. With shares trading below book value and a negative Enterprise Value of -$2.38 million, the key question for investors is whether its 0%…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.